Martin B R, Mechoulam R, Razdan R K
Virginia Commonwealth University, Richmond 23298-0613, USA.
Life Sci. 1999;65(6-7):573-95. doi: 10.1016/s0024-3205(99)00281-7.
The characterization of cannabinoid receptors and signal transduction mechanisms provided the impetus for the searching for endogenous ligands for this system. The result was a family of fatty acid derivatives that interact with cannabinoid receptors to varying degrees. The two ligands that have received the most attention are anandamide (AN) and 2-arachidonolyl-glycerol (Ara-Gl). They are both present in central as well as peripheral tissues. Mechanisms for the synthesis and metabolism of AN have been described. Presently, the physiological stimuli for production and release of AN are unknown. As a result, elucidation of its physiological role remains elusive. However, it seems reasonable to conclude that both AN and 2-Ara-Gl interact with cannabinoid receptors in both peripheral and central tissue to produce a wide range of effects. Administration of these ligands to laboratory animals produce effects that are quite similar to those elicited by delta9-tetrahydrocannabinol (THC), the psychoactive constituent in marijuana. Nevertheless, there are some pharmacological differences between the plant-derived THC and the endogenous cannabinoids that could be due to either pharmadynamic or pharmacokinetics dissimilarities. Extensive structure-activity relationship studies have provided some vital insights into the actions of the endogenous ligands. First and foremost, systematic structural alterations in AN have additional support that it is acting at the cannabinoid receptors in a fashion similar to that of THC. Development of metabolically stable analogs of AN, as well as those with greater receptor affinity, have helped substantiate AN and THC similarities. Nevertheless, pharmacological differences remain between the endogenous and exogenous ligands. Whether these differences are due to the nature of their interaction with the cannabinoid receptors, activation of unique signaling pathways, interactions with non-cannabinoid receptors, or pharmacokinetic considerations remain to be resolved.
大麻素受体及其信号转导机制的特性为寻找该系统的内源性配体提供了动力。结果是发现了一类脂肪酸衍生物,它们与大麻素受体有不同程度的相互作用。受到最多关注的两种配体是花生四烯乙醇胺(AN)和2-花生四烯酰甘油(Ara-Gl)。它们在中枢和外周组织中均有存在。已经描述了AN的合成和代谢机制。目前,AN产生和释放的生理刺激尚不清楚。因此,对其生理作用的阐明仍然难以捉摸。然而,可以合理地得出结论,AN和2-Ara-Gl在周围和中枢组织中均与大麻素受体相互作用,从而产生广泛的影响。将这些配体给予实验动物所产生的效应与δ9-四氢大麻酚(THC,大麻中的精神活性成分)所引发的效应非常相似。然而,植物来源的THC与内源性大麻素之间存在一些药理学差异,这可能是由于药效学或药代动力学的不同所致。广泛的构效关系研究为内源性配体的作用提供了一些重要的见解。首先,AN的系统性结构改变进一步证明它以类似于THC的方式作用于大麻素受体。AN代谢稳定类似物以及具有更高受体亲和力类似物的开发,有助于证实AN与THC的相似性。然而,内源性和外源性配体之间仍然存在药理学差异。这些差异是由于它们与大麻素受体相互作用的性质、独特信号通路的激活、与非大麻素受体的相互作用还是药代动力学因素,仍有待解决。